Venetoclax

Drug Profile

Venetoclax

Alternative Names: A-1195425.0; ABT 199; GDC-0199; RG-7601; RO-5537382; Venclexta; VENCLYXTO

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Abbott Laboratories; Genentech; Walter and Eliza Hall Institute of Medical Research
  • Developer AbbVie; Dana-Farber Cancer Institute; Genentech; Janssen Research & Development; Nantes University Hospital; Pharmacyclics; Roche
  • Class Antineoplastics; Benzamides; Heterocyclic bicyclo compounds; Piperazines; Pyrans; Pyridines; Pyrroles; Small molecules; Sulfonamides
  • Mechanism of Action Apoptosis stimulants; Proto-oncogene protein c-bcl-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Diffuse large B cell lymphoma; Chronic lymphocytic leukaemia; Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia
  • Phase III Acute myeloid leukaemia; Mantle-cell lymphoma; Multiple myeloma
  • Phase II Diffuse large B cell lymphoma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
  • Phase I/II Follicular lymphoma
  • Phase I Breast cancer; Systemic lupus erythematosus

Most Recent Events

  • 24 Aug 2017 Roche initiates enrolment in a phase I trial in Diffuse large B-cell lymphoma (Refractory metastatic disease, Second-line therapy or greater, Combination therapy) in USA (NCT03255096)
  • 07 Aug 2017 AbbVie plans a phase I trial for Cancer (Refractory metastatic disease, In neonates, In infants, In children, In adolescents, In adults) in USA (NCT03236857)
  • 31 Jul 2017 Venetoclax receives Breakthrough Therapy status for Acute myeloid leukaemia (Combination therapy, First-line therapy, In the elderly, In adults) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top